Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%
Market cap
$6.7B
P/E
102×
Fwd P/E
−108×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
3.85% 9.36% 14.72% 22.40%

+8 more TTM periods

Piotroski F-Score
3 4 7 8
ROA
1.99% 4.82% 10.64% 15.11%
ROIC
2.76% 4.36% 31.75% 36.01%
Return on Tangible Assets
6.13% 15.59% 15.03% 22.38%
Average Days of Receivables
99.91 95.23 82.61 85.03
Free Cash Flow per Share
1.33 1.33 2.92 2.97
Free Cash Flow
222.71 221.18 481.42 490.91
Other line items

Show all line items

Columns are period end dates